Neurochemical properties of psilocybin in comparison to ketamine in vivo - A. Wojtas; A. Bysiek; Z. Szych; M. Herian; K. Gołembiowska (Neuroscience Applied, 2021)

Differential effects of repeated treatment with DOI and psilocybin on the head-twitch response (HTR), locomotor activity and anxiety-like behaviour - E. Stojek; Jack Prenderville; F. Dunphy-Doherty (Neuroscience Applied, 2021)

Effects of psilocybin in relative and global cerebral blood flow and behavioural correlates - Nathalie M. Rieser; Ladina P Gubser; Franz X. Vollenweider; Meyer Lars; Katrin H. Preller (Neuroscience Applied, 2021)

Neurochemical and behavioural characterisation of the psychedelic 5HT2AR agonist psilocybin in mice - Ines Erkizia-Santamaría; R. Alles-Pascual; Igor Horrillo; Albert Adell; J. Javier Meana; J.E. Ortega (Neuroscience Applied, 2021)

The effect of psilocybin and sleep manipulation on neuroplasticity and sleep architecture in rats - Lucie Olejníková; Klára Šíchová; K. Chona; Hynek Danda; Tomáš Páleníček (Neuroscience Applied, 2021)

The role of psilocybin in memory consolidation in the animal model - K. Šíchová; K. Chona; Lucie Olejníková Ladislavová; T. Páleníček (Neuroscience Applied, 2021)

Acute change in functional brain entropy following psilocybin administration in healthy volunteers - Drummond E-Wen McCulloch; Anders Smærup Olsen; Dea Siggaard Stenbæk; Sophia Armand; M.K. Madsen; Gitte M. Knudsen; Patrick M. Fisher (Neuroscience Applied, 2021)

Psilocybin may be effective for treatment-resistant depression (Pharmaceutical journal/The pharmaceutical journal, 2021)

Psilocybin: a psychedelic alternative to antidepressants? (Pharmaceutical journal/The pharmaceutical journal, 2021)

Exploratory review of psilocybin usage and awareness amongst college students and potential consumer goods tradeoffs resulting from increased usage - Russell J. Zwanka (International Journal of Research in Marketing Management and Sales, 2021)

Conformational Analysis of Psilocybin: A Computational Approach - Poonam Bhadoria; Manish K. Tripathi; V. Ramanathan (SSRN Electronic Journal, 2021)

Comparison of subjective, autonomic, and endocrine effects of LSD and psilocybin in healthy subjects - Friederike Holze; Laura Ley; F. Müller; V. Nimmy; Anne Eckert; Matthias E. Liechti (Neuroscience Applied, 2021)

Investigating cue-reactivity as biomarker for treatment success in psilocybin-assisted therapy for alcohol use disorder - Nathalie M. Rieser; Ladina P Gubser; C. Rossgoderer Da Silva; Franz X. Vollenweider; Marcus Herdener; Katrin H. Preller (Neuroscience Applied, 2021)

The efficacy of COMP360 psilocybin therapy in treatment-resistant depression: exploratory results from a phase IIb randomised controlled trial - G. Goodwin; Scott T. Aaronson; Boadie W. Dunlop; D. Feifel; David J. Hellerstein; L. Marwood; S. Mistry; Metten Somers; S.C. Stansfield; J. Tsai; S. Williams; Allan H. Young; et al. (Neuroscience Applied, 2021)

The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a phase IIb randomised controlled trial - G.M. Goodwin; Scott T. Aaronson; Boadie W. Dunlop; David Feifel; David J. Hellerstein; N. Hewitt; L. Marwood; S. Mistry; Metten Somers; S.C. Stansfield; J. Tsai; S. Williams; et al. (Neuroscience Applied, 2021)

Pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of oral psilocybin administration in healthy subjects - Friederike Holze; A. Becker; Karolina E. Kolaczynska; Urs Duthaler; Matthias E. Liechti (Neuroscience Applied, 2021)

Selling the Priceless Mushroom: A History of Psilocybin Mushroom Trade in the Sierra Mazateca (Oaxaca) - Marcos Garcia de Teresa (Journal of Illicit Economies and Development, 2021)

An Interpretative Phenomenological Analysis of the use of psilocybin by veterans with symptoms of trauma - F. N. Smith; Joanna C. Neill; Verity Wainwright (Drug Science Policy and Law, 2021)

Rats hallucinate in a similar manner to humans after psilocin - Vejmola Č.; Syrová K.; Šíchová K.; Vlastimil K.; Klučková T.; Kelemen E.; Páleníček T. (Neuroscience Applied, 2021)

Unravelling a New Conformer of Psilocin Through Computational Methods - Bhadoria Poonam; Venkatnarayan Ramanathan (SSRN Electronic Journal, 2021)

Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms. - Garcia-Romeu A; Darcy S; Jackson H; White T; Rosenberg P (Current topics in behavioral neurosciences, 2021)

Dosing Psychedelics and MDMA. - Liechti ME; Holze F. (2021)

Psilocybin for the Treatment of Obsessive-Compulsive Disorders. - Ehrmann K; Allen JJB; Moreno FA. (2021)

Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach. - Agin-Liebes G; Davis AK. (Current topics in behavioral neurosciences, 2021)

Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets. - Sousa TR; Rema J; Machado S; Novais F. (Current Topics in Medicinal Chemistry, 2021)

Psychedelic medicines for mood disorders: current evidence and clinical considerations. - Sarris J; Pinzon Rubiano D; Day K; Galvão-Coelho NL; Perkins D. (PubMed, 2021)

Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action. - Rieser NM; Herdener M; Preller KH (Current topics in behavioral neurosciences, 2021)

The Potential of Psychedelics for End of Life and Palliative Care. - Yaden DB; Nayak SM; Gukasyan N; Anderson BT; Griffiths RR (Current topics in behavioral neurosciences, 2021)

Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples. - Sherwood AM; Kargbo RB; Kaylo KW; Cozzi NV; Meisenheimer P; Kaduk JA. (Acta Crystallographica Section C Structural Chemistry, 2021)

Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension. - Jones GM; Nock MK. (Journal of Psychopharmacology, 2021)

Psilocybin Conspectus: Status, Production Methods, and Considerations. - Plotnik L; Gibbs G; Graham T. (International journal of medicinal mushrooms, 2021)

Psychedelics in the Treatment of Headache and Chronic Pain Disorders. - Schindler EAD. (2021)

Psychedelics and Anti-inflammatory Activity in Animal Models. - Flanagan TW; Nichols CD (Current topics in behavioral neurosciences, 2021)

Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation. - Johnson MW. (2021)

Psilocybin for Trauma-Related Disorders. - Khan AJ; Bradley E; O'Donovan A; Woolley J. (2021)

[A Novel System for Discovering High-affinity Antibody Mutants That Enables Immunoassays with Higher Sensitivities -Development and Application of Clonal Array Profiling (CAP)]. - Kiguchi Y. (YAKUGAKU ZASSHI, 2021)

Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States. - Raison CL; Jain R; Penn AD; Cole SP; Jain S (Frontiers in psychiatry, 2021)

Corrigendum: Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes. - Matzopoulos R; Morlock R; Morlock A; Lerer B; Lerer L (Frontiers in psychiatry, 2021)

Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default. - Yaden DB; Earp D; Graziosi M; Friedman-Wheeler D; Luoma JB; Johnson MW (Frontiers in psychology, 2021)

The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences. - Frymann T; Whitney S; Yaden DB; Lipson J (Frontiers in psychology, 2021)

Editorial: Psychedelic sociality: Pharmacological and extrapharmacological perspectives. - Roseman L; Preller KH; Fotiou E; Winkelman MJ (Frontiers in pharmacology, 2021)

Neuroimaging Correlates of Treatment Response with Psychedelics in Major Depressive Disorder: A Systematic Review. - Kuburi S; Di Passa AM; Tassone VK; Mahmood R; Lalovic A; Ladha KS; Dunlop K; Rizvi S; Demchenko I; Bhat V. (2021)

Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States. - Davis AK; Agin-Liebes G; España M; Pilecki B; Luoma J (Journal of psychoactive drugs, 2021)

Classic psychedelics, health behavior, and physical health. - Simonsson O; Hendricks PS; Chambers R; Osika W; Goldberg SB (Therapeutic advances in psychopharmacology, 2021)

The economics of psychedelic-assisted therapies: A research agenda. - Marseille E; Bertozzi S; Kahn JG (Frontiers in psychiatry, 2021)

Editorial: Old and new psychoactive substances: Pharmacology and potential applications. - Mayer FP; Luethi D; Areal LB; Sitte HH (Frontiers in psychiatry, 2021)

Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action? - Husain MI; Ledwos N; Fellows E; Baer J; Rosenblat JD; Blumberger DM; Mulsant BH; Castle DJ (Frontiers in psychiatry, 2021)

A systematic literature review of clinical trials and therapeutic applications of ibogaine. - Köck P; Froelich K; Walter M; Lang U; Dürsteler KM. (2021)

LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2021)

Predictors of Psychedelic Experience: A Thematic Analysis - McCartney A; McGovern H; De Foe A. (PsyArXiv, 2021)

Predictors of Psychedelic Experience: A Thematic Analysis (PsyArXiv, 2021)

Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies. - Niles H; Fogg C; Kelmendi B; Lazenby M (BMC palliative care, 2021)

A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production. - McKernan K; Kane L; Helbert Y; Zhang L; Houde N; McLaughlin S. (F1000Res, 2021)

Psilocybin modulation of dynamic functional connectivity is associated with plasma psilocin and subjective effects - Olsen AS; Lykkebo-Valløe A; Ozenne B; Madsen MK; Stenbæk DS; Armand S; Mørup M; Ganz M; Knudsen GM; Fisher PM. (medRxiv, 2021)

Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study. - Marschall J; Fejer G; Lempe P; Prochazkova L; Kuchar M; Hajkova K; van Elk M. (Journal of Psychopharmacology, 2021)

Double-blind Placebo-controlled Naturalistic Study of Microdosing With Psilocybin: Effects on Brain Activity, Behavior, Cognition, Creativity, and Mental Health - National Council of Scientific; Technical Research; Argentina (ClinicalTrials.gov, 2021)

Beating pain with psychedelics: Matter over mind? - Elman I; Pustilnik A; Borsook D. (2021)

Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history. - Pearson C; Siegel J; Gold JA. (2021)

Effects of Psilocybin in Major Depressive Disorder - Johns Hopkins University (ClinicalTrials.gov, 2021)

A Quantitative and Qualitative Report of Psilocybin Induced Mystical-Type Experiences and Their Relation to Lasting Positive Effects - McCulloch DE; Grzywacz MZ; Madsen MK; Jensen PS; Ozenne B; Armand S; Knudsen GM; Fisher PM; Stenbæk DS. (PsyArXiv, 2021)

A Quantitative and Qualitative Report of Psilocybin Induced Mystical-Type Experiences and Their Relation to Lasting Positive Effects (PsyArXiv, 2021)

1H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids? - Vilca-Melendez S; Uthaug MV; Griffin JL. (2021)

Microevidence for microdosing with psilocybin mushrooms: a double-blind placebo-controlled study of subjective effects, behavior, creativity, perception, cognition, and brain activity - Cavanna F; Muller S; de la Fuente LA; Zamberlan F; Palmucci M; Janeckova L; Kuchar M; Pallavicini C; Tagliazucchi E. (bioRxiv, 2021)

A Spectrum of Selves Reinforced in Multilevel Coherence: A Contextual Behavioural Response to the Challenges of Psychedelic-Assisted Therapy Development. - Whitfield HJ. (Frontiers in Psychiatry, 2021)

P.0593 Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals - Drummond E-Wen McCulloch; M. Madsen; Dea Siggaard Stenbæk; Søren Kristiansen; Brice Ozenne; P.S. Jensen; Gitte M. Knudsen; Patrick M. Fisher (European Neuropsychopharmacology, 2021)

P.0353 Study protocol: psilocybin as a treatment for anorexia nervosa: a pilot study - Hannah Douglass; Meg J. Spriggs; R.J. Park; Tim Read; Jennifer L. Danby; Frederico José Coelho de Magalhães; Kirsty L. Alderton; Adèle Lafrance; Dasha Nicholls; David Erritzøe; David Nutt; Robin Carhart-Harris (European Neuropsychopharmacology, 2021)

P.0421 Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - study design, rationale and current status - Lea J. Mertens; Michael Koslowski; Felix Betzler; Ricarda Evens; Maria Gilles; Andrea Jungaberle; Henrik Jungaberle; Tomislav Majić; Max Wolff; Andreas Ströhle; Stefan Wellek; Gerhard Gründer (European Neuropsychopharmacology, 2021)

P.0828 Psilocybin enhances emotional response to music in healthy individuals - Dea Siggaard Stenbæk; M. Madsen; Sophia Armand; Catharina Messel; Maria Zofia Grzywacz; David Erritzøe; Gitte M. Knudsen; Patrick M. Fisher (European Neuropsychopharmacology, 2021)

P.0298 Evaluation of the acute mechanism of action of psilocybin in mice - Ines Erkizia-Santamaría; R. Alles-Pascual; Igor Horrillo; J. Javier Meana; Jorge E. Ortega (European Neuropsychopharmacology, 2021)

P.0623 The clinical relevance of the pharmacokinetics of psilocybin - A. Andreiev; E. Bucuci; James Chue; Charl Els; Pierre Chue (European Neuropsychopharmacology, 2021)

P.0885 The effect of psilocybin therapy for depression on low-frequency brain activity in response to music - Matthew B. Wall; Cynthia Lam; Natalie Ertl; Mendel Kaelen; Leor Roseman; David Nutt; Robin Carhart-Harris (European Neuropsychopharmacology, 2021)

P.0729 Highlights of psychedelic history and current research on psilocybin application for treatment of depression - a comprehensive literature review - Sara Penedos; Caio Freitas Ramos; María José López Miguel; Márcio José Martins Alves; Luciana Campos Paulino; Adriano Valério S. Azevêdo; M. Magalhães; L. Moreno; N. Ribeiro; Inês Fonseca; Ana Margarida Romão Franco; Luís Madruga; et al. (European Neuropsychopharmacology, 2021)

P.0553 Effect of chronic microdosing of psilocin on cell proliferation and behavior in rats - Olejníková L.; Danda H.; Lhotková E.; Kútná V.; Šíchová K.; Syrová K.; Mazochová K.; Páleníček T. (European Neuropsychopharmacology, 2021)

P.0858 Psilocin induces perceptual alterations in rats: visual discrimination study - Vejmola Č.; Syrová K.; Koudelka V.; Šíchová K.; Tesař M.; Dodoková A.; Kelemen E.; Páleníček T. (European Neuropsychopharmacology, 2021)

Homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use? - Gibbons WJ; McKinney MG; O'Dell PJ; Bollinger BA; Jones JA. (Bioengineered, 2021)

Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial. - Rucker J; Jafari H; Mantingh T; Bird C; Modlin NL; Knight G; Reinholdt F; Day C; Carter B; Young A. (BMJ Open, 2021)

Molecular insights into psychedelic drug action. - Slocum ST; DiBerto JF; Roth BL. (2021)

Microevidence for microdosing with psilocybin mushrooms: a double-blind placebo-controlled study of subjective effects, behavior, creativity, perception, cognition, and brain activity - Enzo Tagliazucchi (Zenodo (CERN European Organization for Nuclear Research), 2021)

Interaction Profiles of Central Nervous System Active Drugs at Human Organic Cation Transporters 1-3 and Human Plasma Membrane Monoamine Transporter. - Angenoorth TJF; Stankovic S; Niello M; Holy M; Brandt SD; Sitte HH; Maier J (International journal of molecular sciences, 2021)

Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies - Weleff J; Akiki TJ; Barnett BS. (medRxiv, 2021)

Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors. - Strumila R; Nobile B; Korsakova L; Lengvenyte A; Olie E; Lopez-Castroman J; Guillaume S; Courtet P. (2021)

Examining attitudes to psilocybin: Should candidates for medical psilocybin be required to pass a contextual suitability test - Molumby M; Gaynor K; Guerin S. (PsyArXiv, 2021)

Examining attitudes to psilocybin: Should candidates for medical psilocybin be required to pass a contextual suitability test (PsyArXiv, 2021)

Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review. - Schimmers N; Breeksema JJ; Smith-Apeldoorn SY; Veraart J; van den Brink W; Schoevers RA. (2021)

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. - Becker AM; Holze F; Grandinetti T; Klaiber A; Toedtli VE; Kolaczynska KE; Duthaler U; Varghese N; Eckert A; Grünblatt E; Liechti ME. (Clinical Pharmacology & Therapeutics, 2021)

Researchers hope psilocybin could improve quit rates for smokers - Gary Enos (Alcoholism & Drug Abuse Weekly, 2021)

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. - Rootman JM; Kryskow P; Harvey K; Stamets P; Santos-Brault E; Kuypers KPC; Polito V; Bourzat F; Walsh Z. (Scientific Reports, 2021)

Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism. - Meinhardt MW; Pfarr S; Fouquet G; Rohleder C; Meinhardt ML; Barroso-Flores J; Hoffmann R; Jeanblanc J; Paul E; Wagner K; Hansson AC; Köhr G; et al. (Science Advances, 2021)

Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. - Ling S; Ceban F; Lui LMW; Lee Y; Teopiz KM; Rodrigues NB; Lipsitz O; Gill H; Subramaniapillai M; Mansur RB; Lin K; Ho R; et al. (2021)

Human behavioral pharmacology of psychedelics. - Strickland JC; Johnson MW. (2021)

[Rapid-acting antidepressants-neurobiological mechanisms of action]. - Gass P; Vasilescu AN; Inta D. (2021)

Daily briefing: Largest trial shows psilocybin is effective to treat depression. - Graham F. (Nature, 2021)

Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. - Doss MK; Považan M; Rosenberg MD; Sepeda ND; Davis AK; Finan PH; Smith GS; Pekar JJ; Barker PB; Griffiths RR; Barrett FS. (Translational Psychiatry, 2021)

Psilocybin steps closer to credibility - Sam Wong (The New Scientist, 2021)

Policy in focus: Is psilocybin the next cannabis? - Basky G. (Canadian Medical Association Journal, 2021)

Psilocybin Induces Aberrant Prediction Error Processing of Tactile Mismatch Responses-A Simultaneous EEG-FMRI Study. - Duerler P; Brem S; Fraga-González G; Neef T; Allen M; Zeidman P; Stämpfli P; Vollenweider FX; Preller KH. (Cerebral Cortex, 2021)

From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders. - Kozlowska U; Nichols C; Wiatr K; Figiel M. (2021)

Study Protocol for "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study". - Spriggs MJ; Douglass HM; Park RJ; Read T; Danby JL; de Magalhães FJC; Alderton KL; Williams TM; Blemings A; Lafrance A; Nicholls DE; Erritzoe D; et al. (Frontiers in Psychiatry, 2021)

The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder - Maryland Oncology Hematology; PA (ClinicalTrials.gov, 2021)

Case Report: Magic Mushroom (Psilocybe Cubensis) Intoxication - Andrian Fajar Kusumadewi (Archives of The Medicine and Case Reports, 2021)

Psychedelics and Mindfulness: A Systematic Review and Meta-Analysis - Radakovic C; Radakovic R; Peryer G; Geere J. (PsyArXiv, 2021)

Psychedelics and Mindfulness: A Systematic Review and Meta-Analysis (PsyArXiv, 2021)

Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis. - Yu CL; Yang FC; Yang SN; Tseng PT; Stubbs B; Yeh TC; Hsu CW; Li DJ; Liang CS. (2021)

United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020. - Barnett BS; Parker SE; Weleff J. (2021)

Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults. - Murray CH; Tare I; Perry CM; Malina M; Lee R; de Wit H. (2021)

Psilocin, LSD, mescaline, and DOB all induce broadband desynchronization of EEG and disconnection in rats with robust translational validity. - Vejmola Č; Tylš F; Piorecká V; Koudelka V; Kadeřábek L; Novák T; Páleníček T. (Translational Psychiatry, 2021)

Many Drugs of Abuse May Be Acutely Transformed to Dopamine, Norepinephrine and Epinephrine In Vivo. - Fitzgerald PJ (International journal of molecular sciences, 2021)

6.3 CURRENT RESEARCH ON PSILOCYBIN TREATMENT ON END-OF-LIFE ANXIETY AND MDMA TREATMENT OF SOCIAL ANXIETY IN AUTISM SPECTRUM DISORDER - Charles S. Grob (Journal of the American Academy of Child & Adolescent Psychiatry, 2021)

Magic mushroom: all is not as it seems. - Castro BN; Prata Saraiva R; Afonso João D; Dantas Costa S (Acta chirurgica Belgica, 2021)

Analysis of Five Mushroom Toxins in Blood by UPLC-HRMS. - Liu WQ; Shi Y; Xiang P; Yu F; Xie B; Dong M; Ha J; Ma CL; Wen D. (2021)

A potential effect of psilocybin on anxiety in neurotic personality structures in adolescents. - Bogadi M; Kaštelan S. (Croatian Medical Journal, 2021)

Novel antidepressant drugs: Beyond monoamine targets. - Gonda X; Dome P; Neill JC; Tarazi FI. (2021)

The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies. - Castelhano J; Lima G; Teixeira M; Soares C; Pais M; Castelo-Branco M. (2021)

Psychedelics, Sociality, and Human Evolution. - Rodríguez Arce JM; Winkelman MJ. (Frontiers in Psychology, 2021)

Psilocybin in the treatment of anorexia nervosa: The English transition of a French 1959 case study - Vincent Verroust; Rayyan Zafar; Meg J. Spriggs (Annales Médico-psychologiques revue psychiatrique, 2021)

Rediscovering Psilocybin as an Antidepressive Treatment Strategy. - Zeiss R; Gahr M; Graf H. (2021)

Psilocybin: Next to treat depression, OCD and nicotine addiction - Alison Knopf (Alcoholism & Drug Abuse Weekly, 2021)

Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. - Aleksandrova LR; Phillips AG. (2021)

Testing human hair after magic mushrooms abuse by LC-MS/MS: Pitfalls and limitations - Pascal Kintz; Jean-Sébastien Raul; Alice Ameline (Forensic Chemistry, 2021)

Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. - Li NX; Hu YR; Chen WN; Zhang B. (2021)

Derivatization-assisted enzyme-linked immunosorbent assay for identifying hallucinogenic mushrooms with enhanced sensitivity. - Morita I; Kiguchi Y; Oyama H; Takeuchi A; Tode C; Tanaka R; Ogata J; Kikura-Hanajiri R; Kobayashi N. (2021)

Neuropsychological Functioning in Users of Serotonergic Psychedelics - A Systematic Review and Meta-Analysis. - Basedow LA; Riemer TG; Reiche S; Kreutz R; Majić T. (2021)

Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis. - Leger RF; Unterwald EM. (2021)

Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders. - Kargbo RB. (2021)

Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. - de Vos CMH; Mason NL; Kuypers KPC. (2021)

Treating Major Depression Disorder with Psychedelics: A Potential Therapeutic Application for Psilocybin? - Gonçalo Cotovio; Ana Maia; Ana Velosa; Carolina Seybert; Albino J. Oliveira-Maia (Revista Portuguesa de Psiquiatria e Saúde Mental, 2021)

Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems. - Argento E; Christie D; Mackay L; Callon C; Walsh Z. (Frontiers in Psychiatry, 2021)

The Role of Psilocybin-Assisted Psychotherapy to Support Patients With Cancer: A Critical Scoping Review of the Research. - Lehto RH; Miller M; Sender J. (Journal of Holistic Nursing, 2021)

Spiritual experiences in psychedelic-assisted psychotherapy: Case reports of communion with the divine, the departed, and saints in research using psilocybin for the treatment of alcohol dependence. - Samantha K. Podrebarac; Kelley C. O’Donnell; Sarah E. Mennenga; Lindsey T. Owens; Tara C. Malone; Jessie H. Duane; Michael P. Bogenschutz (Spirituality in Clinical Practice, 2021)

Treatment-Resistant Depression: Approaches to Treatment. - Kverno KS; Mangano E. (2021)

A Complex Impact of Systemically Administered 5-HT2A Receptor Ligands on Conditioned Fear. - Hagsäter SM; Pettersson R; Pettersson C; Atanasovski D; Näslund J; Eriksson E. (The International Journal of Neuropsychopharmacology, 2021)

Blinding and expectancy confounds in psychedelic randomized controlled trials. - Muthukumaraswamy SD; Forsyth A; Lumley T. (2021)

Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities. - Yaden DB; Johnson MW; Griffiths RR; Doss MK; Garcia-Romeu A; Nayak S; Gukasyan N; Mathur BN; Barrett FS (The international journal of neuropsychopharmacology, 2021)

Use of alternative therapy with Psilocybin in oncologic patients with depression and/or anxiety disorders - integrative review - Frederico Marques Silveira; Amanda Pereira Mendes; Mayara Rodrigues dos Santos; Júlia Ramos Cerchi; IRIS TIYONO TAVARES UMEDA; Breno Basílio de Melo; Luiza Elena Casaburi; Mateus Nóbrega Oliveira; Douglas Reis Abdalla (Research Society and Development, 2021)

Spontaneous Spiritual Awakenings: Phenomenology, Altered States, Individual Differences, and Well-Being. - Corneille JS; Luke D. (Frontiers in Psychology, 2021)

Therapeutic interventions for PTSD - current evidence on the the role of psychedelics - Figueiredo I; Viegas F; Ferreira F; Santos A; Ramos J; Miranda J. (2021)

Psychedelics and psychiatric disorders: A emerging role - Peixoto C; Santos F; Rego D; Medeiros H. (2021)

Treating addiction with psychedelics - are we waking up? - Miranda J; Barbosa M; Figueiredo I; Mota P; Tarelho A. (2021)

Psychedelics: A new era of treatment? - Torres S. (2021)

Effects of psilocybin-assisted therapy on treatment-resistant depression - Fraga A; Esteves-Sousa D; Facucho-Oliveira J; Albuquerque M; Costa M; Dos Santos P; Moura N; Moutinho A. (2021)

Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far? - Descalço N; Medeiros A; Santos C; Borges G. (2021)

Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review. - Więckiewicz G; Stokłosa I; Piegza M; Gorczyca P; Pudlo R. (2021)

Effects of Ayahuasca on Personality: Results of Two Randomized, Placebo-Controlled Trials in Healthy Volunteers. - Mendes Rocha J; Rossi GN; Osório FL; Bouso Saiz JC; Silveira GO; Yonamine M; Crevelin EJ; Queiroz ME; Cecílio Hallak JE; Dos Santos RG. (Frontiers in Psychiatry, 2021)

Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells. - Nkadimeng SM; Steinmann CML; Eloff JN. (DOAJ (DOAJ: Directory of Open Access Journals), 2021)

Use of hallucinogens in Slovakia: Does it differ from global trends? - Lukačovič M; Masaryk R. (2021)

Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports. - Nayak SM; Gukasyan N; Barrett FS; Erowid E; Erowid F; Griffiths RR. (Pharmacopsychiatry, 2021)

Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells - Sanah Malomile Nkadimeng; Christiaan ML Steinmann; J.N. Eloff (Journal of Inflammation Research, 2021)

Mit Psilocybin gegen Depression - Markus Weih (InFo Neurologie + Psychiatrie, 2021)

Migraine prevalence in visual snow with prior illicit drug use (hallucinogen persisting perception disorder) versus without. - van Dongen RM; Alderliefste GJ; Onderwater GLJ; Ferrari MD; Terwindt GM (European journal of neurology, 2021)

Pharmacologic Similarities and Differences Among Hallucinogens. - Waters K. (The Journal of Clinical Pharmacology, 2021)

The cranial windows of perception. - DiBerto JF; Roth BL. (2021)

Psilocybin for Depression. - Wiley JF; Bei B. (2021)

The Potential Role of Serotonergic Hallucinogens in Depression Treatment. - Psiuk D; Nowak E; Cholewa K; Łopuszańska U; Samardakiewicz M. (2021)

A Case Series Describing the Tale of ‘The Magic Mushroom’; An Increasing Trend of Psychedelic Misuse Among Substance Abusers in Terengganu - Chong Siew Koon; Tuan Sharipah binti Tuan Hadi; Izatt Syafieq bin Abd Rashad; Ruzila binti Ali (2021)

Serotonin Heteroreceptor Complexes and Their Integration of Signals in Neurons and Astroglia-Relevance for Mental Diseases. - Borroto-Escuela DO; Ambrogini P; Narvaez M; Di Liberto V; Beggiato S; Ferraro L; Fores-Pons R; Alvarez-Contino JE; Lopez-Salas A; Mudò G; Díaz-Cabiale Z; Fuxe K. (2021)

Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. - Yaden DB; Berghella AP; Regier PS; Garcia-Romeu A; Johnson MW; Hendricks PS. (2021)

Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy. - Horton DM; Morrison B; Schmidt J. (2021)

A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility Study - King's College London (ClinicalTrials.gov, 2021)

Both partners practicing orgasmic meditation report having a mystical-type experience: results using the Mystical Experience Questionnaire - Siegel V; Emmert-Aronson B. (F1000Res, 2021)

Verbal behavior related to drug reinforcement in polysubstance cannabis users: Comparison across drugs. - Cox DJ; Johnson MW. (2021)

Exploring the Use of Psilocybin Therapy for Existential Distress: A Qualitative Study of Palliative Care Provider Perceptions. - Mayer CE; LeBaron VT; Acquaviva KD. (Journal of Psychoactive Drugs, 2021)

Naturalistic Entheogenics: Précis of Philosophy of Psychedelics - Letheby C. (PsyArXiv, 2021)

Naturalistic Entheogenics: Précis of Philosophy of Psychedelics (PsyArXiv, 2021)

Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. - Madsen MK; Stenbæk DS; Arvidsson A; Armand S; Marstrand-Joergensen MR; Johansen SS; Linnet K; Ozenne B; Knudsen GM; Fisher PM. (European Neuropsychopharmacology, 2021)

Structure Elucidation and Spectroscopic Analysis of Chromophores Produced by Oxidative Psilocin Dimerization. - Lenz C; Dörner S; Sherwood A; Hoffmeister D. (Chemistry - A European Journal, 2021)

Trial of psilocybin does not show major difference from antidepressant (The Brown University Psychopharmacology Update, 2021)

Psilocybin for Depression: The ACE Model Manual - Watts R. (PsyArXiv, 2021)

Psilocybin for Depression: The ACE Model Manual (PsyArXiv, 2021)

Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. - Shao LX; Liao C; Gregg I; Davoudian PA; Savalia NK; Delagarza K; Kwan AC. (Neuron, 2021)

A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production. - Kevin McKernan; Liam T. Kane; Yvonne Helbert; Lei Zhang; Nathan Houde; Stephen McLaughlin (Zenodo (CERN European Organization for Nuclear Research), 2021)

Psilocybin Therapy May Work as Well as Common Antidepressant - Z C (Scientific American, 2021)

A dynamic and multilocus metabolic regulation strategy using quorum-sensing-controlled bacterial small RNA. - Bao SH; Jiang H; Zhu LY; Yao G; Han PG; Wan XK; Wang K; Song TY; Liu CJ; Wang S; Zhang ZY; Zhang DY; et al. (Cell Reports, 2021)

Sensitive quantitative analysis of psilocin and psilocybin in hair samples from suspected users and their distribution in seized hallucinogenic mushrooms - Zhou Liying; Xiang Ping; Wen Di; Shen Baohua; Wang Xin; Li Le; Deng Hongxiao; Chen Hang; Yan Hui; Shen Min; Shi Yan; Liu Wanhui (Forensic Toxicology, 2021)

Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals. - McCulloch DE; Madsen MK; Stenbæk DS; Kristiansen S; Ozenne B; Jensen PS; Knudsen GM; Fisher PM. (Journal of Psychopharmacology, 2021)

Sustained, Multifaceted Improvements in Mental Well-Being Following Psychedelic Experiences in a Prospective Opportunity Sample. - Mans K; Kettner H; Erritzoe D; Haijen ECHM; Kaelen M; Carhart-Harris RL. (Frontiers in Psychiatry, 2021)

Psilocybin for Treating Psychiatric Disorders: Is it a Psychonaut Legend or a Promising Therapeutic Perspective? - Coppola M; Bevione F; Mondola R. (Preprints.org, 2021)

Psychedelic Assisted Therapy for Major Depressive Disorder: A Review - McCartney A; McGovern H; De Foe A. (PsyArXiv, 2021)

Psychedelic Assisted Therapy for Major Depressive Disorder: A Review (PsyArXiv, 2021)

Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa - Sarah-Catherine Rodan; Phillip Aouad; Iain S. McGregor; Sarah Maguire (OBM Neurobiology, 2021)

Psilocybin: the magic medicine for depression? - Corrigan A; Burchill E; Pelton L; Marrocu A; Mazzoleni A; Shackshaft L. (2021)

Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study. - Révész D; Ona G; Rossi GN; Rocha JM; Dos Santos RG; Hallak JEC; Alcázar-Córcoles MÁ; Bouso JC. (Frontiers in Psychiatry, 2021)

A draft reference assembly of the Psilocybe cubensis genome - McKernan K; Kane LT; Crawford S; Chin C; Trippe A; McLaughlin S. (F1000Res, 2021)

Psychedelic perceptions: mental health service user attitudes to psilocybin therapy. - Corrigan K; Haran M; McCandliss C; McManus R; Cleary S; Trant R; Kelly Y; Ledden K; Rush G; O'Keane V; Kelly JR. (Irish Journal of Medical Science (1971 -), 2021)

Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials - Prochazkova L; van Elk M; Marschall JC; Rifkin BD; Fejer G; Schoen N; Fiacchino D; Kuchar M; Hommel B. (PsyArXiv, 2021)

Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials (PsyArXiv, 2021)

Participant Reports of Mindfulness, Posttraumatic Growth, and Social Connectedness in Psilocybin-Assisted Group Therapy: An Interpretive Phenomenological Analysis - Gabrielle Agin-Liebes; Eve Ekman; B. Anderson; Maxx Malloy; Alexandra Haas; Josh Woolley (Journal of Humanistic Psychology, 2021)

Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses - McCulloch DE; Knudsen GM; Barrett FS; Doss M; Deco G; Carhart-Harris R; Rosas F; Preller K; Ramaekers J; Mason N; Müller F; Fisher PM. (PsyArXiv, 2021)

Further development of a liquid chromatography-high-resolution mass spectrometry/mass spectrometry-based strategy for analyzing eight biomarkers in human urine indicating toxic mushroom or Ricinus communis ingestions. - Bambauer TP; Wagmann L; Weber AA; Meyer MR. (2021)

Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses (PsyArXiv, 2021)

Psilocybin: A brief overview for psychiatric mental health nurse practitioners. - Fradkin D. (Perspectives In Psychiatric Care, 2021)

Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies. - Fogg C; Michaels TI; de la Salle S; Jahn ZW; Williams MT. (Experimental and Clinical Psychopharmacology, 2021)

Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives. - Cox DJ; Garcia-Romeu A; Johnson MW. (The American Journal of Drug and Alcohol Abuse, 2021)

Psilocybin: the magic medicine for depression? - Amber Elyse Corrigan; Ella Burchill; Lucy Pelton; Alessia Marrocu; Adele Mazzoleni; Lydia Shackshaft (BJPsych Open, 2021)

Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders - Chao YS; Horton J. (Canadian Agency for Drugs and Technologies in Health, Ottawa (ON), 2021)

Spontaneous Spiritual Awakenings: Phenomenology, Altered States, Individual Differences, and Wellbeing - Corneille JS; Luke D. (PsyArXiv, 2021)

Spontaneous Spiritual Awakenings: Phenomenology, Altered States, Individual Differences, and Wellbeing (PsyArXiv, 2021)

Psychedelics and health behaviour change. - Teixeira PJ; Johnson MW; Timmermann C; Watts R; Erritzoe D; Douglass H; Kettner H; Carhart-Harris RL. (2021)

Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach. - Magaraggia I; Kuiperes Z; Schreiber R. (2021)

Decreased brain modularity after psilocybin therapy for depression. - Daws R; Timmerman C; Giribaldi B; Sexton J; Wall M; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R. (Research Square, 2021)

Future Directions for Clinical Psilocybin Research: The Relaxed Symptom Network (PsyArXiv, 2021)